Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Should Lift Iressa Restrictions, Washington Legal Foundation Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Study data that aggregate the experience of many patients do not reflect the value of gefinitib in certain subgroups, WLF says in comments to the agency.

You may also be interested in...



AstraZeneca's Iressa Use Narrowed: No New Commercial Patients

Revised labeling for the oncologic restricts use to patients who have already received the drug and benefited from it, as well as certain clinical trial participants. Beginning Sept. 15, Iressa patients will have to refill prescriptions through a single mail order pharmacy.

Iressa Survival Data Adequately Disseminated To Physicians/Patients, Cmte. Says

AstraZeneca communication to physicians/patients on Iressa survival data has been adequate, FDA Oncologic Drugs Advisory Committee says. FDA asks committee to discuss possibility of recommending Genentech/OSI Pharma’s Tarceva as alternative to Iressa in labeling, but committee resists.

Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal

A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability

Topics

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel